Searched for: person:petljm01
in-biosketch:yes
Disagreement on foundational principles of biological aging
Gladyshev, Vadim N; Anderson, Benjamin; Barlit, Hanna; Barré, Benjamin; Beck, Samuel; Behrouz, Bahareh; Belsky, Daniel W; Chaix, Amandine; Chamoli, Manish; Chen, Brian H; Cheng, Kaiyang; Chuprin, Jane; Churchill, Gary A; Cipriano, Andrea; Colville, Alex; Deelen, Joris; Deigin, Yuri; Edmonds, KeHuan K; English, Bradley W; Fang, Ruogu; Florea, Michael; Gershteyn, Iosif M; Gill, Diljeet; Goetz, Laura H; Gorbunova, Vera; Griffin, Patrick T; Horvath, Steve; Borch Jensen, Martin; Jin, Xin; Jovanovska, Sara; Kajderowicz, Kathrin M; Kasahara, Tomoko; Kerepesi, Csaba; Kulkarni, Subhash; Labunskyy, Vyacheslav M; Levine, Morgan E; Libert, Sergiy; Lu, J Yuyang; Lu, Yuancheng Ryan; Marioni, Riccardo E; McCoy, Brianah M; Mitchell, Wayne; Moqri, Mahdi; Nasirian, Farzaneh; Niimi, Peter; Oh, Hamilton Se-Hwee; Okundaye, Brian; Parkhitko, Andrey A; Peshkin, Leonid; Petljak, Mia; Poganik, Jesse R; Pridham, Glen; Promislow, Daniel E L; Prusisz, Weronika; Quiniou, Margaux; Raj, Ken; Richard, Daniel; Ricon, Jose Luis; Rutledge, Jarod; Scheibye-Knudsen, Morten; Schork, Nicholas J; Seluanov, Andrei; Shadpour, Michael; Shindyapina, Anastasia V; Shuken, Steven R; Sivakumar, Sruthi; Stoeger, Thomas; Sugiura, Ayumu; Sutton, Nadia R; Suvorov, Alexander; Tarkhov, Andrei E; Teeling, Emma C; Trapp, Alexandre; Tyshkovskiy, Alexander; Unfried, Maximilian; Ward-Caviness, Cavin K; Yim, Sun Hee; Ying, Kejun; Yunes, Jeffrey; Zhang, Bohan; Zhavoronkov, Alex
To gain insight into how researchers of aging perceive the process they study, we conducted a survey among experts in the field. While highlighting some common features of aging, the survey exposed broad disagreement on the foundational issues. What is aging? What causes it? When does it begin? What constitutes rejuvenation? Not only was there no consensus on these and other core questions, but none of the questions received a majority opinion-even regarding the need for consensus itself. Despite many researchers believing they understand aging, their understanding diverges considerably. Importantly, as different processes are labeled as "aging" by researchers, different experimental approaches are prioritized. The survey shed light on the need to better define which aging processes this field should target and what its goals are. It also allowed us to categorize contemporary views on aging and rejuvenation, revealing critical, yet largely unanswered, questions that appear disconnected from the current research focus. Finally, we discuss ways to address the disagreement, which we hope will ultimately aid progress in the field.
PMCID:11630784
PMID: 39660064
ISSN: 2752-6542
CID: 5762652
Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer
Petljak, Mia; Green, Abby M; Maciejowski, John; Weitzman, Matthew D
Mutational signatures associated with apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC)3 cytosine deaminase activity have been found in over half of cancer types, including some therapy-resistant and metastatic tumors. Driver mutations can occur in APOBEC3-favored sequence contexts, suggesting that mutagenesis by APOBEC3 enzymes may drive cancer evolution. The APOBEC3-mediated signatures are often detected in subclonal branches of tumor phylogenies and are acquired in cancer cell lines over long periods of time, indicating that APOBEC3 mutagenesis can be ongoing in cancer. Collectively, these and other observations have led to the proposal that APOBEC3 mutagenesis represents a disease-modifying process that could be inhibited to limit tumor heterogeneity, metastasis and drug resistance. However, critical aspects of APOBEC3 biology in cancer and in healthy tissues have not been clearly defined, limiting well-grounded predictions regarding the benefits of inhibiting APOBEC3 mutagenesis in different settings in cancer. We discuss the relevant mechanistic gaps and strategies to address them to investigate whether inhibiting APOBEC3 mutagenesis may confer clinical benefits in cancer.
PMCID:9700387
PMID: 36280735
ISSN: 1546-1718
CID: 5775692
Mechanisms of APOBEC3 mutagenesis in human cancer cells
Petljak, Mia; Dananberg, Alexandra; Chu, Kevan; Bergstrom, Erik N; Striepen, Josefine; von Morgen, Patrick; Chen, Yanyang; Shah, Hina; Sale, Julian E; Alexandrov, Ludmil B; Stratton, Michael R; Maciejowski, John
The APOBEC3 family of cytosine deaminases has been implicated in some of the most prevalent mutational signatures in cancer1-3. However, a causal link between endogenous APOBEC3 enzymes and mutational signatures in human cancer genomes has not been established, leaving the mechanisms of APOBEC3 mutagenesis poorly understood. Here, to investigate the mechanisms of APOBEC3 mutagenesis, we deleted implicated genes from human cancer cell lines that naturally generate APOBEC3-associated mutational signatures over time4. Analysis of non-clustered and clustered signatures across whole-genome sequences from 251 breast, bladder and lymphoma cancer cell line clones revealed that APOBEC3A deletion diminished APOBEC3-associated mutational signatures. Deletion of both APOBEC3A and APOBEC3B further decreased APOBEC3 mutation burdens, without eliminating them. Deletion of APOBEC3B increased APOBEC3A protein levels, activity and APOBEC3A-mediated mutagenesis in some cell lines. The uracil glycosylase UNG was required for APOBEC3-mediated transversions, whereas the loss of the translesion polymerase REV1 decreased overall mutation burdens. Together, these data represent direct evidence that endogenous APOBEC3 deaminases generate prevalent mutational signatures in human cancer cells. Our results identify APOBEC3A as the main driver of these mutations, indicate that APOBEC3B can restrain APOBEC3A-dependent mutagenesis while contributing its own smaller mutation burdens and dissect mechanisms that translate APOBEC3 activities into distinct mutational signatures.
PMCID:9329121
PMID: 35859169
ISSN: 1476-4687
CID: 5775682
Mapping clustered mutations in cancer reveals APOBEC3 mutagenesis of ecDNA
Bergstrom, Erik N; Luebeck, Jens; Petljak, Mia; Khandekar, Azhar; Barnes, Mark; Zhang, Tongwu; Steele, Christopher D; Pillay, Nischalan; Landi, Maria Teresa; Bafna, Vineet; Mischel, Paul S; Harris, Reuben S; Alexandrov, Ludmil B
Clustered somatic mutations are common in cancer genomes and previous analyses reveal several types of clustered single-base substitutions, which include doublet- and multi-base substitutions1-5, diffuse hypermutation termed omikli6, and longer strand-coordinated events termed kataegis3,7-9. Here we provide a comprehensive characterization of clustered substitutions and clustered small insertions and deletions (indels) across 2,583 whole-genome-sequenced cancers from 30 types of cancer10. Clustered mutations were highly enriched in driver genes and associated with differential gene expression and changes in overall survival. Several distinct mutational processes gave rise to clustered indels, including signatures that were enriched in tobacco smokers and homologous-recombination-deficient cancers. Doublet-base substitutions were caused by at least 12 mutational processes, whereas most multi-base substitutions were generated by either tobacco smoking or exposure to ultraviolet light. Omikli events, which have previously been attributed to APOBEC3 activity6, accounted for a large proportion of clustered substitutions; however, only 16.2% of omikli matched APOBEC3 patterns. Kataegis was generated by multiple mutational processes, and 76.1% of all kataegic events exhibited mutational patterns that are associated with the activation-induced deaminase (AID) and APOBEC3 family of deaminases. Co-occurrence of APOBEC3 kataegis and extrachromosomal DNA (ecDNA), termed kyklonas (Greek for cyclone), was found in 31% of samples with ecDNA. Multiple distinct kyklonic events were observed on most mutated ecDNA. ecDNA containing known cancer genes exhibited both positive selection and kyklonic hypermutation. Our results reveal the diversity of clustered mutational processes in human cancer and the role of APOBEC3 in recurrently mutating and fuelling the evolution of ecDNA.
PMCID:8850194
PMID: 35140399
ISSN: 1476-4687
CID: 5775672
Molecular origins of APOBEC-associated mutations in cancer
Petljak, Mia; Maciejowski, John
The APOBEC family of cytidine deaminases has been proposed to represent a major enzymatic source of mutations in cancer. Here, we summarize available evidence that links APOBEC deaminases to cancer mutagenesis. We also highlight newly identified human cell models of APOBEC mutagenesis, including cancer cell lines with suspected endogenous APOBEC activity and a cell system of telomere crisis-associated mutations. Finally, we draw on recent data to propose potential causes of APOBEC misregulation in cancer, including the instigating factors, the relevant mutator(s), and the mechanisms underlying generation of the genome-dispersed and clustered APOBEC-induced mutations.
PMCID:7494591
PMID: 32818816
ISSN: 1568-7856
CID: 5775662
Tissue-Biased Expansion of DNMT3A-Mutant Clones in a Mosaic Individual Is Associated with Conserved Epigenetic Erosion
Tovy, Ayala; Reyes, Jaime M; Gundry, Michael C; Brunetti, Lorenzo; Lee-Six, Henry; Petljak, Mia; Park, Hyun Jung; Guzman, Anna G; Rosas, Carina; Jeffries, Aaron R; Baple, Emma; Mill, Jonathan; Crosby, Andrew H; Sency, Valerie; Xin, Baozhong; Machado, Heather E; Castillo, Danielle; Weitzel, Jeffrey N; Li, Wei; Stratton, Michael R; Campbell, Peter J; Wang, Heng; Sanders, Mathijs A; Goodell, Margaret A
DNA methyltransferase 3A (DNMT3A) is the most commonly mutated gene in clonal hematopoiesis (CH). Somatic DNMT3A mutations arise in hematopoietic stem cells (HSCs) many years before malignancies develop, but difficulties in comparing their impact before malignancy with wild-type cells have limited the understanding of their contributions to transformation. To circumvent this limitation, we derived normal and DNMT3A mutant lymphoblastoid cell lines from a germline mosaic individual in whom these cells co-existed for nearly 6 decades. Mutant cells dominated the blood system, but not other tissues. Deep sequencing revealed similar mutational burdens and signatures in normal and mutant clones, while epigenetic profiling uncovered the focal erosion of DNA methylation at oncogenic regulatory regions in mutant clones. These regions overlapped with those sensitive to DNMT3A loss after DNMT3A ablation in HSCs and in leukemia samples. These results suggest that DNMT3A maintains a conserved DNA methylation pattern, the erosion of which provides a distinct competitive advantage to hematopoietic cells.
PMID: 32673568
ISSN: 1875-9777
CID: 5775652
Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis
Petljak, Mia; Alexandrov, Ludmil B; Brammeld, Jonathan S; Price, Stacey; Wedge, David C; Grossmann, Sebastian; Dawson, Kevin J; Ju, Young Seok; Iorio, Francesco; Tubio, Jose M C; Koh, Ching Chiek; Georgakopoulos-Soares, Ilias; Rodríguez-Martín, Bernardo; Otlu, Burçak; O'Meara, Sarah; Butler, Adam P; Menzies, Andrew; Bhosle, Shriram G; Raine, Keiran; Jones, David R; Teague, Jon W; Beal, Kathryn; Latimer, Calli; O'Neill, Laura; Zamora, Jorge; Anderson, Elizabeth; Patel, Nikita; Maddison, Mark; Ng, Bee Ling; Graham, Jennifer; Garnett, Mathew J; McDermott, Ultan; Nik-Zainal, Serena; Campbell, Peter J; Stratton, Michael R
Multiple signatures of somatic mutations have been identified in cancer genomes. Exome sequences of 1,001 human cancer cell lines and 577 xenografts revealed most common mutational signatures, indicating past activity of the underlying processes, usually in appropriate cancer types. To investigate ongoing patterns of mutational-signature generation, cell lines were cultured for extended periods and subsequently DNA sequenced. Signatures of discontinued exposures, including tobacco smoke and ultraviolet light, were not generated in vitro. Signatures of normal and defective DNA repair and replication continued to be generated at roughly stable mutation rates. Signatures of APOBEC cytidine deaminase DNA-editing exhibited substantial fluctuations in mutation rate over time with episodic bursts of mutations. The initiating factors for the bursts are unclear, although retrotransposon mobilization may contribute. The examined cell lines constitute a resource of live experimental models of mutational processes, which potentially retain patterns of activity and regulation operative in primary human cancers.
PMID: 30849372
ISSN: 1097-4172
CID: 5775642
Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines [Letter]
Maura, F; Petljak, M; Lionetti, M; Cifola, I; Liang, W; Pinatel, E; Alexandrov, L B; Fullam, A; Martincorena, I; Dawson, K J; Angelopoulos, N; Samur, M K; Szalat, R; Zamora, J; Tarpey, P; Davies, H; Corradini, P; Anderson, K C; Minvielle, S; Neri, A; Avet-Loiseau, H; Keats, J; Campbell, P J; Munshi, N C; Bolli, N
PMCID:5886048
PMID: 29209044
ISSN: 1476-5551
CID: 5775632
Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations
Brammeld, Jonathan S; Petljak, Mia; Martincorena, Inigo; Williams, Steven P; Alonso, Luz Garcia; Dalmases, Alba; Bellosillo, Beatriz; Robles-Espinoza, Carla Daniela; Price, Stacey; Barthorpe, Syd; Tarpey, Patrick; Alifrangis, Constantine; Bignell, Graham; Vidal, Joana; Young, Jamie; Stebbings, Lucy; Beal, Kathryn; Stratton, Michael R; Saez-Rodriguez, Julio; Garnett, Mathew; Montagut, Clara; Iorio, Francesco; McDermott, Ultan
Drug resistance is an almost inevitable consequence of cancer therapy and ultimately proves fatal for the majority of patients. In many cases, this is the consequence of specific gene mutations that have the potential to be targeted to resensitize the tumor. The ability to uniformly saturate the genome with point mutations without chromosome or nucleotide sequence context bias would open the door to identify all putative drug resistance mutations in cancer models. Here, we describe such a method for elucidating drug resistance mechanisms using genome-wide chemical mutagenesis allied to next-generation sequencing. We show that chemically mutagenizing the genome of cancer cells dramatically increases the number of drug-resistant clones and allows the detection of both known and novel drug resistance mutations. We used an efficient computational process that allows for the rapid identification of involved pathways and druggable targets. Such a priori knowledge would greatly empower serial monitoring strategies for drug resistance in the clinic as well as the development of trials for drug-resistant patients.
PMCID:5378179
PMID: 28179366
ISSN: 1549-5469
CID: 5775612
Somatic mutations reveal asymmetric cellular dynamics in the early human embryo
Ju, Young Seok; Martincorena, Inigo; Gerstung, Moritz; Petljak, Mia; Alexandrov, Ludmil B; Rahbari, Raheleh; Wedge, David C; Davies, Helen R; Ramakrishna, Manasa; Fullam, Anthony; Martin, Sancha; Alder, Christopher; Patel, Nikita; Gamble, Steve; O'Meara, Sarah; Giri, Dilip D; Sauer, Torril; Pinder, Sarah E; Purdie, Colin A; Borg, Åke; Stunnenberg, Henk; van de Vijver, Marc; Tan, Benita K T; Caldas, Carlos; Tutt, Andrew; Ueno, Naoto T; van 't Veer, Laura J; Martens, John W M; Sotiriou, Christos; Knappskog, Stian; Span, Paul N; Lakhani, Sunil R; Eyfjörd, Jórunn Erla; Børresen-Dale, Anne-Lise; Richardson, Andrea; Thompson, Alastair M; Viari, Alain; Hurles, Matthew E; Nik-Zainal, Serena; Campbell, Peter J; Stratton, Michael R
Somatic cells acquire mutations throughout the course of an individual's life. Mutations occurring early in embryogenesis are often present in a substantial proportion of, but not all, cells in postnatal humans and thus have particular characteristics and effects. Depending on their location in the genome and the proportion of cells they are present in, these mosaic mutations can cause a wide range of genetic disease syndromes and predispose carriers to cancer. They have a high chance of being transmitted to offspring as de novo germline mutations and, in principle, can provide insights into early human embryonic cell lineages and their contributions to adult tissues. Although it is known that gross chromosomal abnormalities are remarkably common in early human embryos, our understanding of early embryonic somatic mutations is very limited. Here we use whole-genome sequences of normal blood from 241 adults to identify 163 early embryonic mutations. We estimate that approximately three base substitution mutations occur per cell per cell-doubling event in early human embryogenesis and these are mainly attributable to two known mutational signatures. We used the mutations to reconstruct developmental lineages of adult cells and demonstrate that the two daughter cells of many early embryonic cell-doubling events contribute asymmetrically to adult blood at an approximately 2:1 ratio. This study therefore provides insights into the mutation rates, mutational processes and developmental outcomes of cell dynamics that operate during early human embryogenesis.
PMCID:6169740
PMID: 28329761
ISSN: 1476-4687
CID: 5775622